Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
AL

WKN: A417NR | ISIN: CA0028221046 | Ticker: ABL0
Frankfurt
16.11.26 | 08:40
11,900 Euro
+1,71 % +0,200
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ABBOTT LABORATORIES CDR Chart 1 Jahr
5-Tage-Chart
ABBOTT LABORATORIES CDR 5-Tage-Chart

Aktuelle News zur ABBOTT LABORATORIES CDR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:10Here's How Abbott's EP Business Is Shaping Up for the Rest of 20262
ABBOTT LABORATORIES CDR Aktie jetzt für 0€ handeln
MiAbbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator lead5
DiAbbott's conduction system pacing lead nets US, European approvals1
DiNew Abbott Panbio COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season3
DiWhat Are Wall Street Analysts' Target Price for Abbott Stock?6
04.11.ABBOTT LABORATORIES - 10-Q, Quarterly Report24
03.11.Abbott's Tectonic test looks to shift artery disease treatment with 'early' win6
02.11.Abbott Touts Favorable Outcomes In Cardiovascular Device Trials13
02.11.Abbott's next-gen Amulet 360 LAA occluder delivers one-year data3
02.11.Abbott, J&J spotlight clinical successes in coronary intravascular lithotripsy5
02.11.Abbott Laboratories Amulet 360 Achieves 98% Stroke-Free Rate In VERITAS Study791NORTH CHICAGO (dpa-AFX) - Monday, Abbott Laboratories (ABT) announced one-year results for its investigational Amulet 360 Left Atrial Appendage Occluder from the VERITAS study, evaluating the...
► Artikel lesen
02.11.Late-breaking one-year data show Abbott's next-generation Amulet 360 device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke312Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show...
► Artikel lesen
01.11.Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System346SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries...
► Artikel lesen
31.10.Notable analyst calls this week: Broadcom, Moderna and Abbott among top picks36
28.10.FDA approves Abbott's new Amplatzer occluder for paravalvular leaks3
27.10.Abbott downgraded at Argus on guidance cut12
27.10.Argus downgrades Abbott Labs stock rating on guidance cut4
26.10.Abbott launches next-gen ultra-sensitive residual disease test for cancer2
26.10.Abbott Launches Next-Generation Oncodetect Test For Cancer Residual Disease Detection547NORTH CHICAGO (dpa-AFX) - Monday, Abbott Laboratories (ABT), a global healthcare company, announced the commercial availability of its next-generation Oncodetect molecular residual disease (MRD)...
► Artikel lesen
26.10.Abbott launches whole-genome sequencing MRD test for cancer7
1 2 3 4 5 Weiter >>
282 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1